— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.
— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.
— Net product sales were $1.28 billion.
— EYLEA net product sales in the US were $1.22 billion.
— Sanofi and Bayer collaboration revenues were $748 million.
— R&D expenses totaled $683 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Salesforce stock hit by weak guidance, co-CEO’s exit. What next?
For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected
Macy’s (M): Here’s a look at the retailer’s expectations for the near term
Shares of Macy’s Inc. (NYSE: M) were down on Thursday. The stock has gained 36% over the past three months and 18% over the past one month. The company’s sales
KR Earnings: Kroger Q3 sales, profit increase and top expectations
Department store chain The Kroger Co. (NYSE: KR) on Thursday said its third-quarter sales and adjusted earnings increased year-over-year. The latest numbers also exceeded the market's expectations. Net earnings attributable to
